43 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28252961	13	Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.	Goethe-University Frankfurt
27299736	37	The"Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.	St. John'S University
26200813	90	Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma.	Setsunan University
	1	A new structural analogue antagonist of peptido-leukotrienes. The discovery of bay x7195	TBA
16220969	219	Designed multiple ligands. An emerging drug discovery paradigm.	Organon Laboratories
1331447	32	Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure-activity studies leading to the discovery of (+-)-3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl][[3- (dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic	Merck Frosst Centre For Therapeutic Research
1635053	47	5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.	Wyeth-Ayerst Research
19505824	36	Synthesis and structure-activity relationships of gamma-carboline derivatives as potent and selective cysLT(1) antagonists.	Universitat De Barcelona
	2	THE ROLE OF ARGININE IN THE BINDING OF LTD4 ANTAGONISTS TO cysLT1 RECEPTORS OF GUINEA PIG LUNG	TBA
	25	Synthesis and in vitro profile of 7-substituted quinoline chromanols as novel, non-acidic LTB4 antagonists	TBA
	16	Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction	TBA
	38	Evolution of a series of non-quinoline leukotriene D4 receptor antagonist; synthesis and sar of benzothiazoles and thiazoles substituted benzyl alcohols as potent LTD4 antagonists	TBA
	37	The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonists.	TBA
	8	LTD4 Receptor binding activity of novel pyridine chromanols: qualitative correlation with pKa	TBA
	8	Synthesis and pharmacological profile of two novel heterocyclic chromanols, CP-80,798 and CP-85,958, as potent LTD4 receptor antagonists	TBA
	11	The discovery of L-699,392, a novel potent and orally active leukotriene D4 receptor antagonist	TBA
	13	A new series of potent LTD4 antagonists in the styrylquinoline class.	TBA
	47	The discovery of a new structural class of potent orally active leukotriene D4 antagonists	TBA
10669566	53	Derivation of pharmacophore and CoMFA models for leukotriene D(4) receptor antagonists of the quinolinyl(bridged)aryl series.	Laboratorios Menarini
10509933	4	Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.	Pfizer
9934474	9	Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists.	Pfizer
9873560	12	N-carbamoyl analogs of Zafirlukast: potent receptor antagonists of leukotriene D4.	Pfizer
9871521	32	Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class.	Novartis Pharma
9554877	9	Development of a three-dimensional CysLT1 (LTD4) antagonist model with an incorporated amino acid residue from the receptor.	Vrije Universiteit
9554876	23	Synthesis and structure-activity relationships of carboxyflavones as structurally rigid CysLT1 (LTD4) receptor antagonists.	Vrije Universiteit
8176706	27	Synthesis, structure-activity relationships, and pharmacological evaluation of a series of fluorinated 3-benzyl-5-indolecarboxamides: identification of 4-[[5-[((2R)-2-methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methyl indol- 3-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]benzamide, a potent, orall	Zeneca Pharmaceuticals Group
7608912	6	(Piperidinylalkoxy)chromones: novel antihistamines with additional antagonistic activity against leukotriene D4.	Vrije Universiteit
3746809	2	Design and synthesis of sodium (beta R*, gamma S*)-4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl] thio]-gamma-hydroxy-beta-methylbenzenebutanoate: a novel, selective, and orally active receptor antagonist of leukotriene D4.	TBA
3035179	5	High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid.	TBA
2993610	3	Synthesis and pharmacological characterization of 5-(2-dodecylphenyl)-4,6-dithianonanedioic acid and 5-[2-(8-phenyloctyl)phenyl]-4,6-dithianonanedioic acid: prototypes of a novel class of leukotriene antagonists.	TBA
2547071	27	3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists.	Roche Research Center
2502629	90	Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from platelets and their in vivo effects on inflammation and anaphylaxis.	Rorer Central Research
2342072	46	Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.	Ici Pharmaceuticals Group
2170650	4	Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leukotriene D4 receptor antagonist.	Merck Frosst Centre For Therapeutic Research
2157010	35	Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene D4 receptor antagonists. 2. Effects of an additional phenyl ring on receptor affinity.	Rorer Central Research
2157009	49	Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships.	Rorer Central Research
1851845	17	Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene D4 receptor antagonists. 4. Addition of chromone moiety enhances leukotriene D4 receptor binding affinity.	Rhone-Poulenc Rorer Central Research
1849993	13	Peptide leukotrienes: current status of research.	Ici Pharmaceuticals Group